PrabotulinumtoxinA-Xvfs + OnabotulinumtoxinA + PrabotulinumtoxinA-Xvfs

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 25/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Glabellar Frown Lines

Conditions

Glabellar Frown Lines

Trial Timeline

Mar 30, 2022 → May 22, 2023

NCT ID

NCT05320393

About PrabotulinumtoxinA-Xvfs + OnabotulinumtoxinA + PrabotulinumtoxinA-Xvfs

PrabotulinumtoxinA-Xvfs + OnabotulinumtoxinA + PrabotulinumtoxinA-Xvfs is a phase 2 stage product being developed by Evolus for Glabellar Frown Lines. The current trial status is completed. This product is registered under clinical trial identifier NCT05320393. Target conditions include Glabellar Frown Lines.

What happened to similar drugs?

0 of 11 similar drugs in Glabellar Frown Lines were approved

Approved (0) Terminated (0) Active (11)

🔄Placebo + AGN-151586AbbViePhase 3

🔄AGN-151586 + PlaceboAbbViePhase 3

🔄AGN-151586AbbViePhase 3

🔄Botulinum toxin type A + Botulinum toxin type A + Placebo + PlaceboIpsenPhase 3

🔄IPN10200 + PlaceboIpsenPhase 3

🔄Botulinum toxin type A + PlaceboIpsenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05320393	Phase 2	Completed	Mar 30, 2022	May 22, 2023	Glabellar Frown Lines

Competing Products

19 competing products in Glabellar Frown Lines

See all competitors

Product	Company	Stage	Hype Score
AGN-151586 + BOTOX + Placebo	AbbVie	Phase 1	29
Placebo + AGN-151586	AbbVie	Phase 3	40
AGN-151586 + Placebo	AbbVie	Phase 3	40
AGN-151586 + OnabotulinumtoxinA + Placebo	AbbVie	Phase 1	29
AGN-151586 + Placebo	AbbVie	Phase 3	40
AGN-151586	AbbVie	Phase 3	40
AGN-151586 + Placebo	AbbVie	Phase 1	29
Botulinum toxin type A + Botulinum toxin type A + Placebo + Placebo	Ipsen	Phase 3	37
IPN10200 + Placebo	Ipsen	Phase 3	44
Botulinum toxin type A + Placebo	Ipsen	Phase 3	37
Botulinum toxin type A + Botulinum toxin type A + Placebo	Ipsen	Phase 2	32
Botulinum toxin type A + Placebo	Ipsen	Phase 3	37
IPN10200 + Placebo	Ipsen	Phase 3	44
prabotulinumtoxinA	Evolus	Pre-clinical	20
Botulinum toxin, Type A	Evolus	Phase 3	30
DWP-450 (Botulinum purified neurotoxin, Type A)	Evolus	Phase 2	25
Botulinum toxin, Type A	Evolus	Phase 3	30
Botulinum purified neurotoxin, Type A	Evolus	Phase 2	25
prabotulinumtoxinA	Evolus	Phase 1	19